Apr. 11, 2014
Hong Kong-based Lee’s Pharmaceutical Holdings and the Italian company Abiogen Pharma announced on April 11, 2014 that they had signed an agreement for License, Distribution and Supply for marketing of Attila® (Neridronic Acid) throughout China, Hong Kong, Macau and Taiwan.
Under the term of the agreement, Lee’s granted an exclusive license and rights for registering and marketing of two indications - Osteogenesis Imperfecta and Complex Regional Pain Syndrome (also known as Algodistrophy).
The drug is currently registered in Italy and used by patients in 32 European countries under the trade name of Nerixia®.